Symbol
BMY
ISIN
US1101221083
Börse
NYSE
Sektor
Health Care
Marktkapitalisierung
150.364 Mrd. US
Branche
Pharmaceuticals
Dividendenrendite
2.97 %
Ausschüttungsquote
29.68 %
KGV
93.81
KUV (TTM)
3.73
KGVe
8.79
Kursziel
74.76 USD
Symbol
BMY
ISIN
US1101221083
Börse
NYSE
Marktkapitalisierung
150.364 Mrd. USD
Sektor
Health Care
Branche
Pharmaceuticals
Dividendenrendite
2.97 %
Ausschüttungsquote
29.68 %
KGV
93.81
KUV (TTM)
3.73
KGVe
8.79
Kursziel
74.76 USD
Live-Chart (verzögert)
Firmenbeschreibung
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, Checkmate Pharmaceuticals, and Sensyne Health plc; clinical collaboration with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc; a discovery collaboration with Insitro, Inc.; and collaboration with Schrödinger, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb Company Fundamentaldaten
Jahre und Quartale beziehen sich jeweils auf das Geschäftsjahr des Unternehmens. (Das Geschäftsjahr kann ggf. vom Kalenderjahr abweichen.)
Das Geschäftsjahr von Bristol-Myers Squibb Company endet im Dezember.
Gewinn pro Jahr & Quartal (Net Income) in Mrd. USD
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| 2020 | -0.775 | -0.085 | 1.872 | 0.000 | 1.012 |
| 2019 | 1.710 | 1.432 | 1.353 | -1.056 | 3.439 |
| 2018 | 1.486 | 0.373 | 1.901 | 1.160 | 4.920 |
| 2017 | 1.574 | 0.916 | 0.845 | -2.328 | 1.007 |
| 2016 | 1.195 | 1.166 | 1.202 | 0.894 | 4.457 |
| 2015 | 1.186 | -0.130 | 0.706 | -0.197 | 1.565 |
| 2014 | 0.937 | 0.333 | 0.721 | 0.013 | 2.004 |
| 2013 | 0.609 | 0.536 | 0.692 | 0.726 | 2.563 |
| 2012 | 1.101 | 0.645 | -0.711 | 0.925 | 1.960 |
| 2011 | 0.986 | 0.902 | 0.969 | 0.852 | 3.709 |
| 2010 | 0.743 | 0.927 | 0.949 | 0.483 | 3.102 |
Gewinn je Aktie (EPS) pro Jahr & Quartal (non-GAAP)
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 1.72 | 1.63 | 1.63 | 0 | 4.98 |
| 2019 | 1.1 | 1.18 | 1.17 | 1.22 | 4.67 |
| 2018 | 0.94 | 1.01 | 1.09 | 0.94 | 3.98 |
| 2017 | 0.84 | 0.74 | 0.75 | 0.68 | 3.01 |
| 2016 | 0.74 | 0.69 | 0.77 | 0.63 | 2.83 |
| 2015 | 0.71 | 0.53 | 0.39 | 0.38 | 2.01 |
| 2014 | 0.46 | 0.48 | 0.45 | 0.46 | 1.85 |
| 2013 | 0.41 | 0.44 | 0.46 | 0.51 | 1.82 |
| 2012 | 0.64 | 0.48 | 0.41 | 0.47 | 2 |
| 2011 | 0.58 | 0.56 | 0.61 | 0.53 | 2.28 |
| 2010 | 0.56 | 0.54 | 0.59 | 0.47 | 2.16 |
Umsatz pro Jahr & Quartal in Mrd. USD
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 10.781 | 10.129 | 10.54 | 0 | 31.45 |
| 2019 | 5.92 | 6.273 | 6.007 | 7.945 | 26.145 |
| 2018 | 5.193 | 5.704 | 5.691 | 5.973 | 22.561 |
| 2017 | 4.929 | 5.144 | 5.254 | 5.449 | 20.776 |
| 2016 | 4.391 | 4.871 | 4.922 | 5.243 | 19.427 |
| 2015 | 4.041 | 4.163 | 4.069 | 4.287 | 16.56 |
| 2014 | 3.811 | 3.889 | 3.921 | 4.258 | 15.879 |
| 2013 | 3.831 | 4.048 | 4.065 | 4.441 | 16.385 |
| 2012 | 5.251 | 4.443 | 3.736 | 4.191 | 17.621 |
| 2011 | 5.011 | 5.434 | 5.345 | 5.454 | 21.244 |
| 2010 | 4.807 | 4.768 | 4.798 | 5.111 | 19.484 |
Umsatz je Aktie pro Jahr & Quartal
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2020 | 4.77 | 4.48 | 4.60 | 0.00 | 268.80 |
| 2019 | 3.62 | 3.83 | 3.68 | 4.64 | 15.27 |
| 2018 | 3.17 | 3.49 | 3.48 | 3.65 | 13.78 |
| 2017 | 2.95 | 3.12 | 3.19 | 3.30 | 12.58 |
| 2016 | 2.61 | 2.90 | 2.93 | 3.12 | 11.56 |
| 2015 | 2.41 | 2.50 | 2.42 | 2.55 | 9.86 |
| 2014 | 2.29 | 2.33 | 2.35 | 2.55 | 9.51 |
| 2013 | 2.31 | 2.44 | 2.45 | 2.67 | 9.86 |
| 2012 | 3.08 | 2.61 | 2.24 | 2.48 | 10.44 |
| 2011 | 2.92 | 3.16 | 3.12 | 3.18 | 12.37 |
| 2010 | 2.79 | 2.76 | 2.78 | 2.96 | 11.28 |
Gewinn-Wachstum in Prozent
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | -100.00 |
| 2020 | 0.00 | 0.00 | 0.00 | -100.00 | -70.57 |
| 2019 | 47.41 | -16.26 | -5.52 | -178.05 | -30.10 |
| 2018 | 0.00 | -74.90 | 409.65 | -38.98 | 388.58 |
| 2017 | 76.06 | -41.80 | -7.75 | -375.50 | -77.41 |
| 2016 | 0.00 | -2.43 | 3.09 | -25.62 | 184.79 |
| 2015 | 9023.08 | -110.96 | 0.00 | -127.90 | -21.91 |
| 2014 | 29.06 | -64.46 | 116.52 | -98.20 | -21.81 |
| 2013 | -34.16 | -11.99 | 29.10 | 4.91 | 30.77 |
| 2012 | 29.23 | -41.42 | -210.23 | 0.00 | -47.16 |
| 2011 | 104.14 | -8.52 | 7.43 | -12.07 | 19.57 |
| 2010 | -90.69 | 24.76 | 2.37 | -49.10 | -70.65 |
Umsatz-Wachstum in Prozent
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2020 | 35.70 | -6.05 | 4.06 | 0.00 | 0.00 |
| 2019 | -0.89 | 5.96 | -4.24 | 32.26 | 15.89 |
| 2018 | -4.70 | 9.84 | -0.23 | 4.96 | 8.59 |
| 2017 | -5.99 | 4.36 | 2.14 | 3.71 | 6.94 |
| 2016 | 2.43 | 10.93 | 1.05 | 6.52 | 17.31 |
| 2015 | -5.10 | 3.02 | -2.26 | 5.36 | 4.29 |
| 2014 | -14.19 | 2.05 | 0.82 | 8.59 | -3.09 |
| 2013 | -8.59 | 5.66 | 0.42 | 9.25 | -7.01 |
| 2012 | -3.72 | -15.39 | -15.91 | 12.18 | -17.05 |
| 2011 | -1.96 | 8.44 | -1.64 | 2.04 | 9.03 |
| 2010 | -4.49 | -0.81 | 0.63 | 6.52 | -3.67 |
Bristol-Myers Squibb Company Fundamentaldaten
Gewinn pro Jahr & Quartal (Net Income)
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| 2020 | -0.775 | -0.085 | 1.872 | 0.000 | 1.012 |
| 2019 | 1.710 | 1.432 | 1.353 | -1.056 | 3.439 |
| 2018 | 1.486 | 0.373 | 1.901 | 1.160 | 4.920 |
| 2017 | 1.574 | 0.916 | 0.845 | -2.328 | 1.007 |
| 2016 | 1.195 | 1.166 | 1.202 | 0.894 | 4.457 |
| 2015 | 1.186 | -0.130 | 0.706 | -0.197 | 1.565 |
| 2014 | 0.937 | 0.333 | 0.721 | 0.013 | 2.004 |
| 2013 | 0.609 | 0.536 | 0.692 | 0.726 | 2.563 |
| 2012 | 1.101 | 0.645 | -0.711 | 0.925 | 1.960 |
| 2011 | 0.986 | 0.902 | 0.969 | 0.852 | 3.709 |
| 2010 | 0.743 | 0.927 | 0.949 | 0.483 | 3.102 |
Gewinn je Aktie (EPS) pro Jahr & Quartal (non-GAAP)
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 1.72 | 1.63 | 1.63 | 0 | 4.98 |
| 2019 | 1.1 | 1.18 | 1.17 | 1.22 | 4.67 |
| 2018 | 0.94 | 1.01 | 1.09 | 0.94 | 3.98 |
| 2017 | 0.84 | 0.74 | 0.75 | 0.68 | 3.01 |
| 2016 | 0.74 | 0.69 | 0.77 | 0.63 | 2.83 |
| 2015 | 0.71 | 0.53 | 0.39 | 0.38 | 2.01 |
| 2014 | 0.46 | 0.48 | 0.45 | 0.46 | 1.85 |
| 2013 | 0.41 | 0.44 | 0.46 | 0.51 | 1.82 |
| 2012 | 0.64 | 0.48 | 0.41 | 0.47 | 2 |
| 2011 | 0.58 | 0.56 | 0.61 | 0.53 | 2.28 |
| 2010 | 0.56 | 0.54 | 0.59 | 0.47 | 2.16 |
Umsatz pro Jahr & Quartal
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 10.781 | 10.129 | 10.54 | 0 | 31.45 |
| 2019 | 5.92 | 6.273 | 6.007 | 7.945 | 26.145 |
| 2018 | 5.193 | 5.704 | 5.691 | 5.973 | 22.561 |
| 2017 | 4.929 | 5.144 | 5.254 | 5.449 | 20.776 |
| 2016 | 4.391 | 4.871 | 4.922 | 5.243 | 19.427 |
| 2015 | 4.041 | 4.163 | 4.069 | 4.287 | 16.56 |
| 2014 | 3.811 | 3.889 | 3.921 | 4.258 | 15.879 |
| 2013 | 3.831 | 4.048 | 4.065 | 4.441 | 16.385 |
| 2012 | 5.251 | 4.443 | 3.736 | 4.191 | 17.621 |
| 2011 | 5.011 | 5.434 | 5.345 | 5.454 | 21.244 |
| 2010 | 4.807 | 4.768 | 4.798 | 5.111 | 19.484 |
Umsatz je Aktie pro Jahr & Quartal
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2020 | 4.77 | 4.48 | 4.60 | 0.00 | 268.80 |
| 2019 | 3.62 | 3.83 | 3.68 | 4.64 | 15.27 |
| 2018 | 3.17 | 3.49 | 3.48 | 3.65 | 13.78 |
| 2017 | 2.95 | 3.12 | 3.19 | 3.30 | 12.58 |
| 2016 | 2.61 | 2.90 | 2.93 | 3.12 | 11.56 |
| 2015 | 2.41 | 2.50 | 2.42 | 2.55 | 9.86 |
| 2014 | 2.29 | 2.33 | 2.35 | 2.55 | 9.51 |
| 2013 | 2.31 | 2.44 | 2.45 | 2.67 | 9.86 |
| 2012 | 3.08 | 2.61 | 2.24 | 2.48 | 10.44 |
| 2011 | 2.92 | 3.16 | 3.12 | 3.18 | 12.37 |
| 2010 | 2.79 | 2.76 | 2.78 | 2.96 | 11.28 |
Gewinn-Wachstum in Prozent
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | -100.00 |
| 2020 | 0.00 | 0.00 | 0.00 | -100.00 | -70.57 |
| 2019 | 47.41 | -16.26 | -5.52 | -178.05 | -30.10 |
| 2018 | 0.00 | -74.90 | 409.65 | -38.98 | 388.58 |
| 2017 | 76.06 | -41.80 | -7.75 | -375.50 | -77.41 |
| 2016 | 0.00 | -2.43 | 3.09 | -25.62 | 184.79 |
| 2015 | 9023.08 | -110.96 | 0.00 | -127.90 | -21.91 |
| 2014 | 29.06 | -64.46 | 116.52 | -98.20 | -21.81 |
| 2013 | -34.16 | -11.99 | 29.10 | 4.91 | 30.77 |
| 2012 | 29.23 | -41.42 | -210.23 | 0.00 | -47.16 |
| 2011 | 104.14 | -8.52 | 7.43 | -12.07 | 19.57 |
| 2010 | -90.69 | 24.76 | 2.37 | -49.10 | -70.65 |
Umsatz-Wachstum in Prozent
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2020 | 35.70 | -6.05 | 4.06 | 0.00 | 0.00 |
| 2019 | -0.89 | 5.96 | -4.24 | 32.26 | 15.89 |
| 2018 | -4.70 | 9.84 | -0.23 | 4.96 | 8.59 |
| 2017 | -5.99 | 4.36 | 2.14 | 3.71 | 6.94 |
| 2016 | 2.43 | 10.93 | 1.05 | 6.52 | 17.31 |
| 2015 | -5.10 | 3.02 | -2.26 | 5.36 | 4.29 |
| 2014 | -14.19 | 2.05 | 0.82 | 8.59 | -3.09 |
| 2013 | -8.59 | 5.66 | 0.42 | 9.25 | -7.01 |
| 2012 | -3.72 | -15.39 | -15.91 | 12.18 | -17.05 |
| 2011 | -1.96 | 8.44 | -1.64 | 2.04 | 9.03 |
| 2010 | -4.49 | -0.81 | 0.63 | 6.52 | -3.67 |
Bristol-Myers Squibb Company Dividenden-Entwicklung
| Ex-Tag | Record Date | Zahltag | Dividende |
|---|---|---|---|
| 2020-12-31 | 2021-01-04 | 2021-02-01 | 0.49 |
| 2020-10-01 | 2020-10-02 | 2020-11-02 | 0.45 |
| 2020-07-02 | 2020-07-06 | 2020-08-03 | 0.45 |
| 2020-04-02 | 2020-04-03 | 2020-05-01 | 0.45 |
| 2020-01-02 | 2020-01-03 | 2020-02-03 | 0.45 |
| 2019-10-03 | 2019-10-04 | 2019-11-01 | 0.41 |
| 2019-07-03 | 2019-07-05 | 2019-08-01 | 0.41 |
| 2019-04-04 | 2019-04-05 | 2019-05-01 | 0.41 |
| 2019-01-03 | 2019-01-04 | 2019-02-01 | 0.41 |
| 2018-10-04 | 2018-10-05 | 2018-11-01 | 0.4 |
| 2018-07-05 | 2018-07-06 | 2018-08-01 | 0.4 |
| 2018-04-05 | 2018-04-06 | 2018-05-01 | 0.4 |
| 2018-01-04 | 2018-01-05 | 2018-02-01 | 0.4 |
| 2017-10-05 | 2017-10-06 | 2017-11-01 | 0.39 |
| 2017-07-05 | 2017-07-07 | 2017-08-01 | 0.39 |
| 2017-04-05 | 2017-04-07 | 2017-05-01 | 0.39 |
| 2017-01-04 | 2017-01-06 | 2017-02-01 | 0.39 |
| 2016-10-05 | 2016-10-07 | 2016-11-01 | 0.38 |
| 2016-06-29 | 2016-07-01 | 2016-08-01 | 0.38 |
| 2016-03-30 | 2016-04-01 | 2016-05-02 | 0.38 |
Hinterlasse einen Kommentar